

wherein a difference between the first and second interactions indicates that the agent modulates the interaction of the Robo and Slit polypeptides.

28-21.

27. (New) A method of identifying agents which modulate the interaction of a ~~Robo~~^{Second} polypeptide and a Slit polypeptide, said method comprising the steps of:

combining the mixture of claim 8 and a candidate agent under conditions whereby, but for the presence of the agent, the ~~Robo~~^{Second} and ~~Slit~~^{First} polypeptides engage in a first interaction, and determining a second interaction of the ~~Robo~~^{Second} and ~~Slit~~^{First} polypeptides in the presence of the agent,

wherein a difference between the first and second interactions indicates that the agent modulates the interaction of the Robo and Slit polypeptides.

REMARKS

The foregoing amendments to the specification are identical to those made in the parent application Serial No.: 09/191,647 except update the "Cross Reference to Related Application" section of the instant application.

As explained in 09/191,647, these amendments to the specification are intended to address Sequence Listing formalities and to incorporate the sections appended to the application as filed:

(1) by relocating the bodies and headings of Tables 3 and 4 (appended to the specification as filed) to page 6, renumbering them Tables 1 and 2 respectively and reformatting the shaded areas as open boxes.

(2) by renumbering Tables 1 and 2 as filed, as Tables 3 and 4 respectively.

(3) by relocating Tables 5 (A-B) and 6 (appended to the specification as filed) and the text accompanying these tables to page 11, and renumbering Table 5 (A-B) as Table 5.

(4) by relocating the sections entitled "Features of Human Slit Predicted Protein" and "Amino acid identity between Drosophila and Human Slit-1" (appended to the specification as filed) to follow Table 6 and replacing the phrase, "presence of the core sequence ... amino acid" with -presence of a leucine rich core sequence-, deleting the four sentences "The amino flank region ... Cxxxxxx." and deleting ": C[x]C[1-3x]GxC[x]C[x]CxC" in the text of the section entitled "Features of Human Slit Predicted Protein".

(5) by relocating the data of "SEQ ID NO:1 & 2" (appended to the specification as filed) to a section entitled "SEQUENCE LISTING" immediately prior to the claims. The sequences disclosed in this sequence listing are identical to those disclosed in the deleted "SEQ ID NO:1 &

2" and Tables 3 and 4, as originally filed.

In accordance with 37 CFR 1.821(e), please use the computer readable form of the Sequence Listing submitted on April 8, 1999 in Application No. 09/191,647, filed November 13, 1998 as the computer readable form of the Sequence Listing for the instant Application. It is understood that the Patent and Trademark Office will make the necessary change in Application number and filing date for the computer readable form that will be used for the instant Application. The sequence information on the written Sequence Listing enclosed herewith is identical to that recorded in computer readable form filed in the above referenced Application No. 09/191,647 and includes no new matter.

The foregoing amendments introduce no new matter.

Respectfully submitted,
SCIENCE & TECHNOLOGY LAW GROUP



Richard Aron Osman, Ph.D., Reg. No. 36,627
Tel: (650) 343-4341; Fax: (650) 343-4342

0076627-51204500

A